AHP Pondimin Limitations Discussed With FDA While Redux Was Under Review
Executive Summary
Wyeth-Ayerst informally discussed added limitations on Pondimin (fenfluramine) combination use while the Redux (dexfenfluramine) NDA was pending, former Wyeth-Ayerst Director-Medical Affairs Marc Deitch, MD, testified Sept. 7 during the ongoing diet-drug class action suit, Vadino v. American Home Products.